Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has complicated the management of inflammatory bowel diseases (IBD). Objectives: This study aimed to assess the efficacy of different anti-SARS-CoV-2 vaccines under different treatments in IBD patients and identify...
Main Authors: | Tamás Resál, Péter Bacsur, Miklós Horváth, Kata Szántó, Mariann Rutka, Anita Bálint, Anna Fábián, Renáta Bor, Zoltán Szepes, János Fekete, Klaudia Farkas, Pál Miheller, Tamás Molnár |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/17562848231183529 |
Similar Items
-
Ustekinumab is associated with superior treatment persistence but not with higher remission rates vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
by: Péter Bacsur, et al.
Published: (2022-12-01) -
The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
by: Klaudia Farkas, et al.
Published: (2021-04-01) -
Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
by: Péter Bacsur, et al.
Published: (2023-06-01) -
Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments
by: Tamás Resál, et al.
Published: (2023-04-01) -
Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
by: Kata Szántó, et al.
Published: (2018-01-01)